A Phase 3 interventional study of Emicizumab in Severe Hemophilia A, sponsored by Hoffmann-La Roche. Active, not recruiting at 32 sites in 14 countries. Open to participants aged 0 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.
Among the 22 studies testing emicizumab in Hemophilia A, this one is the 8th largest by enrollment, is one of 5 that started in 2021, is one of 11 in phase 3, and was the 12th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
Chulalongkorn University · Sites in Thailand
Ages 3–30 · Men only · Healthy volunteers
Bleeding and Clotting Disorders Institute Peoria, Illinois · Sites in United States
Ages 0–90
Indiana Hemophilia &Thrombosis Center, Inc. · Sites in United States
Ages 5–45 · Men only
Versiti Blood Health · Sites in United States
Ages 0–17
By country, each count listing its studies:
emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 0 Months to 12 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 13 · Phase 4 6
First in 2015; this study’s year is marked. 5 started in 2021.
This study's enrollment of 55 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 22 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Hemophilia A by Hoffmann-La Roche: 5 open now, 8 under way, 4 of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2021, is one of 12 in phase 3, and was the 18th registered.
Hoffmann-La Roche’s Hemophilia A studies by the year they started, since 2012.
2 of the studies testing emicizumab in Hemophilia A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT05500807Bleeding and Clotting Disorders Institute Peoria, IllinoisEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing emicizumab in Hemophilia A, from their registry updates:
Among Hoffmann-La Roche’s 25 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level \<1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Emicizumab
Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control. At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period. During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.
Also known as: Hemlibra, RO5534262, RG6013, ACE910
Model-Based Annualized Bleeding Rate for Treated Bleeds
The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Bleeds
The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for All Bleeds
The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for All Bleeds
The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for All Bleeds
The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
Time frame: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Hemophilia Joint Health Score (HJHS) Total Score at Specified Timepoints During the Long-Term Follow-Up Period
Time frame: At Years 4, 5, 6, 7, and 8 of follow-up
Magnetic Resonance Imaging (MRI) Score of Specific Joints at Specified Timepoints During the Long-Term Follow-Up Period
Time frame: At Years 5 and 8 of follow-up
Incidence and Severity of Adverse Events, With Severity Determined According to World Health Organization (WHO) Toxicity Grading Scale
Time frame: From first dose of emicizumab until study completion (8 years)
Incidence of Thromboembolic Events
Time frame: From first dose of emicizumab until study completion (8 years)
Incidence of Thrombotic Microangiopathy
Time frame: From first dose of emicizumab until study completion (8 years)
Incidence and Severity of of Injection Site Reactions, With Severity Determined According to WHO Toxicity Grading Scale
Time frame: From first dose of emicizumab until study completion (8 years)
Incidence of Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Events
Time frame: From first dose of emicizumab until study completion (8 years)
Incidence of Adverse Events Leading to Study Drug Discontinuation
Time frame: From first dose of emicizumab until study completion (8 years)
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.
Time frame: Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
Change From Baseline in Pulse Rate Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)
Change From Baseline in Respiratory Rate Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)
Change From Baseline in Body Temperature Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)
Change From Baseline in Systolic Blood Pressure Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)
Change From Baseline in Diastolic Blood Pressure Over Time
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53, and annually during the 7-year follow-up period until study completion (up to 8 years)
Plasma Trough Concentrations (Ctrough) of Emicizumab
Time frame: Predose at Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53
Incidence of Anti-Emicizumab Antibodies
Time frame: Weeks 1, 5, 17, 29, 41, and 53, and thereafter as clinically indicated until study completion (up to 8 years)
Incidence of De Novo Development of Factor VIII Inhibitors
As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.
Time frame: As clinically indicated from baseline until study completion (up to 8 years)
| Milestone | Emicizumab |
|---|---|
| Started | 55 |
| Received at least one dose of study drug | 55 |
| Completed 52 weeks in the study | 55 |
| Started the long-term follow-up period | 55 |
| Completed | 0 |
| Not completed | 55 |
| Withdrew: Ongoing in the study | 55 |
The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Model-Based Annualized Bleeding Rate for Treated Bleeds | 0.4 (0.30 to 0.63) |
The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Mean Calculated Annualized Bleeding Rate for Treated Bleeds | 0.5 (0.00 to 4.59) |
The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated bleeds per year | Emicizumab |
|---|---|
| Median Calculated Annualized Bleeding Rate for Treated Bleeds | 0.0 (0.00 to 0.81) |
The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Model-Based Annualized Bleeding Rate for All Bleeds | 2.0 (1.49 to 2.66) |
The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Mean Calculated Annualized Bleeding Rate for All Bleeds | 2.0 (0.24 to 7.22) |
The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| All bleeds per year | Emicizumab |
|---|---|
| Median Calculated Annualized Bleeding Rate for All Bleeds | 1.0 (0.53 to 2.93) |
The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds | NA (NA to NA) |
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds | 0.0 (NA to 3.69) |
The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated spontaneous bleeds per year | Emicizumab |
|---|---|
| Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds | 0.0 (0.00 to 0.00) |
The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Model-Based Annualized Bleeding Rate for Treated Joint Bleeds | 0.0 (0.0 to 0.1) |
The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds | 0.0 (0.00 to 3.75) |
The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.
| Treated joint bleeds per year | Emicizumab |
|---|---|
| Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds | 0.0 (0.00 to 0.00) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.
| Participants | Emicizumab |
|---|---|
| Hemoglobin (Low), Not Low to Not Low | 36 |
| Hemoglobin (Low), Not Low to Grade 1 | 5 |
| Hemoglobin (Low), Not Low to Grade 2 | 5 |
| Hemoglobin (Low), Grade 1 to Not Low | 3 |
| Hemoglobin (Low), Grade 1 to Grade 1 | 3 |
| Hemoglobin (Low), Grade 1 to Grade 3 | 1 |
| Hemoglobin (Low), Grade 1 to Grade 4 | 1 |
| Hemoglobin (Low), Grade 2 to Grade 2 | 1 |
| Neutrophils, Total, Abs. (Low), Not Low to Not Low | 8 |
| Neutrophils, Total, Abs. (Low), Not Low to Grade 1 | 14 |
| Neutrophils, Total, Abs. (Low), Not Low to Grade 2 | 2 |
| Neutrophils, Total, Abs. (Low), Not Low to Grade 3 | 3 |
| Neutrophils, Total, Abs. (Low), Not Low to Grade 4 | 2 |
| Neutrophils, Total, Abs. (Low), Grade 1 to Not Low | 4 |
| Neutrophils, Total, Abs. (Low), Grade 1 to Grade 1 | 7 |
| Neutrophils, Total, Abs. (Low), Grade 1 to Grade 2 | 5 |
| Neutrophils, Total, Abs. (Low), Grade 1 to Grade 3 | 1 |
| Neutrophils, Total, Abs. (Low), Grade 2 to Not Low | 1 |
| Neutrophils, Total, Abs. (Low), Grade 2 to Grade 1 | 2 |
| Neutrophils, Total, Abs. (Low), Grade 2 to Grade 2 | 1 |
| Neutrophils, Total, Abs. (Low), Grade 2 to Grade 3 | 1 |
| Neutrophils, Total, Abs. (Low), Missing to Not Low | 1 |
| Neutrophils, Total, Abs. (Low), Missing to Grade 1 | 1 |
| Neutrophils, Total, Abs. (Low), Missing to Grade 2 | 1 |
| Platelets (Low), Not Low to Not Low | 54 |
| Platelets (Low), Not Low to Grade 2 | 1 |
| Alkaline Phosphatase (High), Not High to Not High | 32 |
| Alkaline Phosphatase (High), Not High to Grade 1 | 6 |
| Alkaline Phosphatase (High), Not High to Grade 2 | 2 |
| Alkaline Phosphatase (High), Not High to Grade 3 | 1 |
| Alkaline Phosphatase (High), Not High to Grade 4 | 3 |
| Alkaline Phosphatase (High), Grade 1 to Not High | 2 |
| Alkaline Phosphatase (High), Grade 1 to Grade 1 | 3 |
| Alkaline Phosphatase (High), Grade 1 to Grade 3 | 1 |
| Alkaline Phosphatase (High), Grade 2 to Not High | 1 |
| Alkaline Phosphatase (High), Grade 2 to Grade 1 | 1 |
| Alkaline Phosphatase (High), Grade 2 to Grade 2 | 1 |
| Alkaline Phosphatase (High), Missing to Not High | 1 |
| Alkaline Phosphatase (High), Missing to Grade 1 | 1 |
| SGPT/ALT (High), Not High to Not High | 43 |
| SGPT/ALT (High), Not High to Grade 1 | 6 |
| SGPT/ALT (High), Not High to Grade 3 | 1 |
| SGPT/ALT (High), Not High to Grade 4 | 1 |
| SGPT/ALT (High), Grade 1 to Grade 1 | 2 |
| SGPT/ALT (High), Grade 1 to Grade 4 | 1 |
| SGPT/ALT (High), Missing to Not High | 1 |
| SGOT/AST (High), Not High to Not High | 31 |
| SGOT/AST (High), Not High to Grade 1 | 11 |
| SGOT/AST (High), Not High to Grade 3 | 2 |
| SGOT/AST (High), Grade 1 to Not High | 2 |
| SGOT/AST (High), Grade 1 to Grade 1 | 8 |
| SGOT/AST (High), Grade 1 to Grade 3 | 1 |
| Blood Urea Nitrogen (High), Not High to Not High | 42 |
| Blood Urea Nitrogen (High), Not High to Grade 1 | 5 |
| Blood Urea Nitrogen (High), Grade 1 to Grade 1 | 2 |
| Blood Urea Nitrogen (High), Missing to Not High | 4 |
| Calcium (High), Not High to Not High | 13 |
| Calcium (High), Not High to Grade 1 | 18 |
| Calcium (High), Grade 1 to Not High | 2 |
| Calcium (High), Grade 1 to Grade 1 | 17 |
| Calcium (High), Grade 1 to Grade 2 | 1 |
| Calcium (High), Grade 2 to Grade 1 | 1 |
| Calcium (High), Missing to Not High | 3 |
| Calcium, Corrected for Albumin (High), Not High to Not High | 32 |
| Calcium, Corrected for Albumin (High), Not High to Grade 1 | 6 |
| Calcium, Corrected for Albumin (High), Grade 1 to Not High | 6 |
| Calcium, Corrected for Albumin (High), Grade 1 to Grade 1 | 5 |
| Calcium, Corrected for Albumin (High), Missing to Not High | 5 |
| Calcium, Corrected for Albumin (High), Missing to Grade 1 | 1 |
| Creatinine (High), Not High to Not High | 53 |
| Creatinine (High), Not High to Grade 1 | 2 |
| Glucose (High), Not High to Not High | 51 |
| Glucose (High), Not High to Grade 1 | 1 |
| Glucose (High), Missing to Not High | 3 |
| Potassium (High), Not High to Not High | 40 |
| Potassium (High), Not High to Grade 1 | 7 |
| Potassium (High), Grade 1 to Not High | 4 |
| Potassium (High), Grade 1 to Grade 3 | 1 |
| Potassium (High), Missing to Not High | 1 |
| Potassium (High), Missing to Grade 1 | 1 |
| Potassium (High), Missing to Grade 3 | 1 |
| Sodium (High), Not High to Not High | 52 |
| Sodium (High), Grade 1 to Not High | 1 |
| Sodium (High), Missing to Not High | 2 |
| Bilirubin (High), Not High to Not High | 43 |
| Bilirubin (High), Not High to Grade 1 | 1 |
| Bilirubin (High), Grade 1 to Not High | 1 |
| Bilirubin (High), Grade 2 to Not High | 3 |
| Bilirubin (High), Grade 3 to Not High | 2 |
| Bilirubin (High), Grade 3 to Grade 1 | 1 |
| Bilirubin (High), Grade 4 to Not High | 1 |
| Bilirubin (High), Grade 4 to Grade 2 | 1 |
| Bilirubin (High), Grade 4 to Grade 3 | 2 |
| Calcium (Low), Not Low to Not Low | 50 |
| Calcium (Low), Not Low to Grade 4 | 2 |
| Calcium (Low), Missing to Not Low | 3 |
| Calcium, Corrected for Albumin (Low), Not Low to Not Low | 47 |
| Calcium, Corrected for Albumin (Low), Not Low to Grade 4 | 2 |
| Calcium, Corrected for Albumin (Low), Missing to Not Low | 6 |
| Glucose (Low), Not Low to Not Low | 44 |
| Glucose (Low), Not Low to Grade 1 | 6 |
| Glucose (Low), Not Low to Grade 2 | 1 |
| Glucose (Low), Grade 1 to Not Low | 1 |
| Glucose (Low), Missing to Not Low | 3 |
| Magnesium (Low), Not Low to Not Low | 50 |
| Magnesium (Low), Grade 1 to Not Low | 2 |
| Magnesium (Low), Missing to Not Low | 3 |
| Phosphorus (Low), Not Low to Not Low | 52 |
| Phosphorus (Low), Missing to Not Low | 3 |
| Postassium (Low), Not Low to Not Low | 52 |
| Postassium (Low), Missing to Not Low | 3 |
| Sodium (Low), Not Low to Not Low | 35 |
| Sodium (Low), Not Low to Grade 1 | 13 |
| Sodium (Low), Grade 1 to Not Low | 1 |
| Sodium (Low), Grade 1 to Grade 1 | 4 |
| Sodium (Low), Missing to Not Low | 1 |
| Sodium (Low), Missing to Grade 1 | 1 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
| micrograms per millilitre (μg/mL) | Emicizumab |
|---|---|
| Week 1 | NA ± NA |
| Week 3 | 36.8 ± 9.8 |
| Week 5 | 62.0 ± 13.4 |
| Week 7 | 62.3 ± 13.5 |
| Week 9 | 64.2 ± 14.4 |
| Week 13 | 66.0 ± 12.0 |
| Week 17 | 65.8 ± 13.1 |
| Week 21 | 65.8 ± 13.9 |
| Week 25 | 65.6 ± 15.1 |
| Week 29 | 63.2 ± 14.6 |
| Week 33 | 64.0 ± 21.5 |
| Week 37 | 63.1 ± 15.8 |
| Week 41 | 62.0 ± 17.6 |
| Week 45 | 59.9 ± 16.6 |
| Week 49 | 57.1 ± 14.7 |
| Week 53 | 56.8 ± 15.3 |
Results for this outcome have not been posted.
As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.
Results for this outcome have not been posted.
Collected over From first dose of emicizumab until the primary completion date cutoff (median [range, min-max] observation period: 101.9 [52.6-119.7] weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Emicizumab | 0/55 (0%) | 16/55 (29.1%) | 54/55 (98.2%) |
| Event | Emicizumab |
|---|---|
| FallInjury, poisoning and procedural complications | 4/55 |
| Head injuryInjury, poisoning and procedural complications | 3/55 |
| BronchiolitisInfections and infestations | 2/55 |
| BronchitisInfections and infestations | 2/55 |
| PneumoniaInfections and infestations | 2/55 |
| TonsillitisInfections and infestations | 2/55 |
| Mouth haemorrhageGastrointestinal disorders | 2/55 |
| Tongue haemorrhageGastrointestinal disorders | 2/55 |
| Ear infectionInfections and infestations | 1/55 |
| LaryngitisInfections and infestations | 1/55 |
| Event | Emicizumab |
|---|---|
| PyrexiaGeneral disorders | 26/55 |
| Upper respiratory tract infectionInfections and infestations | 22/55 |
| NasopharyngitisInfections and infestations | 18/55 |
| COVID-19Infections and infestations | 16/55 |
| FallInjury, poisoning and procedural complications | 16/55 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/55 |
| DiarrhoeaGastrointestinal disorders | 12/55 |
| Injection site reactionGeneral disorders | 11/55 |
| Head injuryInjury, poisoning and procedural complications | 10/55 |
| RashSkin and subcutaneous tissue disorders | 10/55 |
| Age, Continuous(Months) | Emicizumab |
|---|---|
| Mean | 5.0 ± 3.9 |
| Sex: Female, Male(Participants) | Emicizumab |
|---|---|
| Female | 0 |
| Male | 55 |
| Ethnicity (NIH/OMB)(Participants) | Emicizumab |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 49 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Emicizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 1 |
| White | 48 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Feb 2021 to primary completion in May 2023, 27 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 27 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab